Anaveon presents updated data from the Phase I/II study of ANV419 in patients with solid tumors during the ESMO Congress 2022. ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent selectivity. A Phase II program of ANV419 has been initiated in Melanoma and multiple combination trials, including in Multiple Myeloma, are in preparation.
Anaveon, a clinical-stage immuno-oncology company, presented updated clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as new pre-clinical data further elucidating the mode of action of this powerful and selective interleukin-2 (IL-2) agonist, at the European Society for Medical Oncology (ESMO) Congress 2022, taking place in Paris.
26 patients in 9 dosing cohorts with different cancers progressing after standard therapy, received ANV419 once every 14 days at doses up to 243 µg/kg in two-week cycles as an intravenous infusion over 15 minutes without pre-medication. ANV419 is well tolerated, and all drug related events were reversible and responsive to supportive care therapy.
In this heavily pre-treated population, 5 patients continue to receive ANV419 treatment. At ANV419 doses ≥108 µg/kg, 75% of patients achieved at least disease stabilization. One patient who is still on ANV419 treatment, had a partial response after two weeks of ANV419 treatment, with 31% shrinkage of tumour mass and a sustained and deepening response with 56% shrinkage at 3 months of ANV419 treatment.
Potential to become a clinically important therapy
Dr. Elena Garralda at the Hospital Universitari Vall d'Hebron in Barcelona, and lead investigator on the study said, “These early data are encouraging and I believe ANV419 has the potential to be a clinically important therapy for patients with different tumor types, both as monotherapy and in combination.”
“We are very excited by the safety, selectivity and preliminary efficacy of ANV419 which builds on the data that we presented at AACR earlier this year,” added Christoph Bucher, MD, Chief Medical Officer of Anaveon. “At doses equivalent to high dose IL-2, ANV419 maintains a safety and pharmacokinetic profile which will enable us to select the most effective dose level without incurring the side effects seen by other IL-2 therapies. We will now initiate our Phase II program investigating the efficacy of ANV419 in Melanoma and Multiple Myeloma and look forward to demonstrating the full therapeutic potential of ANV419 for patients.”
Please login or sign up to comment.
Commenting guidelines